These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23052979)

  • 1. [Trospium chloride once daily for overactive bladder syndrome: results of a multicenter observational study].
    Notz HJ; Hautumm B; Werdier D; Groves R; Odenthal KP
    Urologe A; 2013 Jan; 52(1):65-70. PubMed ID: 23052979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects.
    Harnett MD; Shipley J; MacLean L; Schwiderski U; Sandage BW
    Clin Drug Investig; 2013 Feb; 33(2):133-41. PubMed ID: 23203138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
    Staskin D; Sand P; Zinner N; Dmochowski R;
    J Urol; 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4. PubMed ID: 17632131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
    Staskin DR; Rosenberg MT; Sand PK; Zinner NR; Dmochowski RR
    Int J Clin Pract; 2009 Dec; 63(12):1715-23. PubMed ID: 19930332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.
    Sand PK; Rovner ES; Watanabe JH; Oefelein MG
    Drugs Aging; 2011 Feb; 28(2):151-60. PubMed ID: 21275440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release trospium chloride improves quality of life in overactive bladder.
    Dmochowski RR; Rosenberg MT; Zinner NR; Staskin DR; Sand PK
    Value Health; 2010; 13(2):251-7. PubMed ID: 19818062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
    Ginsberg DA; Oefelein MG; Ellsworth PI
    Neurourol Urodyn; 2011 Apr; 30(4):563-7. PubMed ID: 21268101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study.
    Ivchenko A; Bödeker RH; Neumeister C; Wiedemann A
    BMC Urol; 2018 Sep; 18(1):80. PubMed ID: 30217174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
    Dmochowski RR; Sand PK; Zinner NR; Staskin DR
    Urology; 2008 Mar; 71(3):449-54. PubMed ID: 18342185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.
    Sand PK; Johnson Ii TM; Rovner ES; Ellsworth PI; Oefelein MG; Staskin DR
    BJU Int; 2011 Feb; 107(4):612-20. PubMed ID: 20707790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome.
    Sand PK; Dmochowski RR; Zinner NR; Staskin DR; Appell RA
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Dec; 20(12):1431-8. PubMed ID: 19727537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
    Bödeker RH; Madersbacher H; Neumeister C; Zellner M
    BMC Urol; 2010 Sep; 10():15. PubMed ID: 20840754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
    MacDiarmid SA; Ellsworth PI; Ginsberg DA; Oefelein MG; Sussman DO
    Urology; 2011 Jan; 77(1):24-9. PubMed ID: 20970833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New once-daily formulation for trospium in overactive bladder.
    Chapple C
    Int J Clin Pract; 2010 Oct; 64(11):1535-1540. PubMed ID: 20846201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
    Staskin DR; Cardozo L
    Int J Clin Pract; 2009 Jun; 63(6):973-6. PubMed ID: 19459997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
    Metello J; Nogueira B; Torgal M; Colaço J; Vieira A; Gonçalves V; Retto H
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Sep; 18(9):1021-5. PubMed ID: 17211528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release.
    Chancellor MB; Oefelein MG; Vasavada S
    Neurourol Urodyn; 2010 Apr; 29(4):551-4. PubMed ID: 19634167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.